Our Clinical Practice Services Team continued their focus on raising awareness of myeloma in primary care. This included launching a guide for GPs and highlighting the importance of early diagnosis at national conferences.
The Patient Advocacy team are researching how delays in diagnosing myeloma affect patients’ quality of life. The research will inform a policy report to make NHS and Government decision makers aware of the link between delayed diagnosis and quality of life.
Myeloma UK funded a research project to find out if an app, The ChoiceApp©, could help UK patients with their treatment decisions. As part of the project, the app was shared with small groups of myeloma patients and haematologists to assess whether this approach could benefit UK myeloma patients.
The University of Oxford is looking for MGUS (monoclonal gammopathy of undetermined significance), smouldering myeloma and Waldenstrom’s macroglobulinemia patients to join the OxPLoreD study.
In June, the first results from the OPTIMUM/MUK nine clinical trial were presented at international conferences.
The trial is the first to use state-of-the-art diagnostics and genetic profiling to screen for patients with high-risk myeloma.
These results show that treatment with a five-drug induction treatment (Dara-CVRd) and stem cell transplant is effective and well tolerated in ultra-high risk myeloma patient
Throughout 2021, the Patient Advocacy Team have been continuing their work to support patient access to new treatments on the NHS. Read more about the four active Health Technology Appraisals including the first-ever appraisal for an AL amyloidosis treatment.
Find out more about the educational resources our Clinical Practice Services Team have been developing to raise HCP awareness of myeloma.
New treatments for myeloma continue to come through the appraisal pipeline. In the last few months, there have been several new treatment approvals from both the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC), which is excellent news for patients. Hopefully, there will be more good news for patients throughout 2021…
